Within the limitations of a meta-analysis, a useful work advancing that PCI may have a hitherto masked or hidden mortality
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Coronary Disease - PCI
October 26, 2020
October 12, 2020
An analysis, from the cardiology viewpoint, of the MI nomenclature issues around the external validity of the EXCEL trial that undermined the EACTS support of the relevant 2018 guidelines
September 15, 2020
An open-access large metanalysis on the utility and risks of antiplatelets after PCI. Of note, mortality was not a primary endpoint. The message is that long dual antiplatelet use is an exchange between avoidance of myocardial events and serious bleeding.
The novel oral anticoagulants may enter the arena soon..
April 3, 2020
In the ISCHEMIA Trial, 5179 patients with moderate or severe myocardial ischemia were randomized equally into two groups based on initial management strategy: initial invasive strategy (angiography and revascularization when feasible) and medical therapy, or initial conservative strategy (medical therapy alone and angiography if medical therapy faile
January 10, 2020
''CABG was significantly better than PCI (p=0·0066........''
December 19, 2019
Following the withdrawal of the support of EACTS for the left main stem chapter of the EACTS/ESC Chapter of the revascularisation guidelines following the BBC Newsnight documentary of this, and the withdrawal of Professor David Taggart as an author of the EXCEL trial published in the NEJM, the EXCEL trial authors have published a very robust defence
November 18, 2019
An editorial related to a recent randomized controlled trial suggesting a striking benefit of anti-inflammatory secondary prevention after recent myocardial events.
November 6, 2019
In this randomized trial, percutaneous coronary intervention and CABG had equivalent outcomes for the composite of death, stroke, or myocardial infarction at five years for patients with left main disease of low or intermediate anatomical complexity.
October 19, 2019
Quite interesting to see that the incidence of revascularisation after multivessel PCA (the additional element on the second co-primary outcome) appears to have occured in more than 1% of the patients within three years...
October 18, 2019
Using data from the FREEDOM (Future Revascularizaiton Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease) trial, the authors developed an 8 variable model that predicts individual risk of major acute cardiovascular events in diabetic patients with multivessel disease.